Uric Acid Lowering Effect of Losartan in Patients with Stage 1 Hypertension and Asymptomatic Hyperuricemia
Year: 2024
Type: article
Study design: Clinical Trial
Abstract: Hyperuricemia is a recognized risk factor for cardiovascular diseases, particularly prevalent in individuals with hypertension.Addressing hyperuricemia holds the potential to mitigate the onset of hypertension.This investigation focused on exploring the uric acid-reducing capabilities of losartan in patients exhibiting stage 1 hypertension (as per JNC VIII) accompanied by asymptomatic hyperuricemia.Conducted as a community-based before-and-after interventional study, this research involved 27 male participants with stage 1 hypertension and asymptomatic hyperuricemia.The intervention comprised a treatment regimen of losartan, initially at 25 mg once daily for 4 weeks, followed by an escalation to 50 mg once daily for the subsequent 4 weeks, totaling 8 weeks of continuous therapy.Serum uric acid levels were assessed at baseline, after 4 weeks of 25 mg losartan, and following an additional 4 weeks of 50 mg losartan therapy.Comparative analysis with baseline data revealed a significant reduction in blood pressure with both losartan doses, although serum uric acid level did not show a significant decrease.Notably, the dose-dependent effect on serum uric acid level was evident, with a 1.80 % reduction after 4 weeks of 25 mg losartan and a 6.52 % reduction after 4 weeks of 50 mg losartan.In summary, while losartan demonstrated a dose-dependent effect in lowering uric acid levels, achieving normal range values may necessitate larger doses and extended therapy duration.
Institution: Defence Services Medical Academy
Language: English
Subfield: Nephrology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4392000008